ArticleScientific reports2020
Identification of a newly isolated lytic bacteriophage against K24 capsular type, carbapenem resistant Klebsiella pneumoniae isolates.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- Isolation and characterization of novel bacteriophages with broad-spectrum lytic activity against carbapenem-resistant Klebsiella pneumoniae capsular pathotypes K1, K2, K3, K5, and K20.Biology direct · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Isolation, characterization, and genomic analysis of novel bacteriophage AEV23 against multidrug-resistant Klebsiella pneumoniae isolated from Cystic Fibrosis patients.BMC microbiology · 2026Article
- Broth Optical Density-Based Assessment for Phage Therapy: Turbidity Reduction, Antibacterial Virulence, and Time-Kill.Viruses · 2026Review
- Phage and endolysin-based inhibition ofFrontiers in cellular and infection microbiology · 2026Review
- Novel bacteriophages effectively target multidrug-resistant clinical isolates of Klebsiella pneumoniae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Comparative genomic insights into multidrug resistance in classical and hypervirulent K. pneumoniae clinical isolates.Scientific reports · 2025Article
- Isolation and characterization of an antibiofilm bacteriophage against Klebsiella michiganensis and evaluation of its therapeutic potential in an insect larval gut colonization model.BMC microbiology · 2025Article
- Phage therapy for antimicrobial-resistant Klebsiella spp. infections: a review of mechanisms, synergies, and clinical potential.Archives of microbiology · 2025Review
- Phage-induced protection against lethal bacterial reinfection.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Phage-antibiotic synergy to combat multidrug resistant strains of Gram-negative ESKAPE pathogens.Scientific reports · 2025Article
- Isolation, characterization, and genomic analysis of phage MY02 targeting extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.Archives of virology · 2025Article
- Phage therapy for Klebsiella pneumoniae: Understanding bacteria-phage interactions for therapeutic innovations.PLoS pathogens · 2025Review
- Genomic and proteomic characterization of four novel Schitoviridae family phages targeting uropathogenic Escherichia coli strain.Virology journal · 2025Article
- Analysis of a novel phage as a promising biological agent targeting multidrug resistant Klebsiella pneumoniae.AMB Express · 2025Article
- Isolation, Characterization, and Anti-Biofilm Activity of a NovelAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Isolation of the novel phage SAP71 and its potential use against Staphylococcus aureus in an atopic dermatitis mouse model.Virus genes · 2024Article
- Characterization of Newly Isolated Bacteriophages Targeting Carbapenem-Resistant Klebsiella pneumoniae.Journal of microbiology (Seoul, Korea) · 2024Article
- Exploring the resistome, virulome, and mobilome of multidrug-resistant Klebsiella pneumoniae isolates: deciphering the molecular basis of carbapenem resistance.BMC genomics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing incidence of carbapenemase-producing K. pneumoniae strains (CP-Kps) in the last decade has become a serious global healthcare problem. Therapeutic options for the treatment of emerging hospital clones have drastically narrowed and therefore novel approaches must be considered. Here we have isolated and characterized a lytic bacteriophage, named vB_KpnS_Kp13, that was effective against all Verona integron-encoded metallo-β-lactamase (VIM) producing K. pneumoniae isolates originating from hospital samples (urine, blood, sputum and faeces), belonging to the ST15 clonal lineage and expressing the K24 capsule. Morphological characterization of vB_KpnS_Kp13 showed that the newly identified phage belonged to the Siphoviridae family, and phylogenetic analysis showed that it is part of a distinct clade of the Tunavirinae subfamily. Functional analysis revealed that vB_KpnS_Kp13 had relatively short latent period times (18 minutes) compared to other K. pneumoniae bacteriophages and could degrade biofilm by more than 50% and 70% in 24 and 48 hours respectively. Complete in vivo rescue potential of the new phage was revealed in an intraperitoneal mouse model where phages were administered intraperitoneally 10 minutes after bacterial challenge. Our findings could potentially be used to develop specific anti-CP-Kps bacteriophage-based therapeutic strategies against major clonal lineages and serotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.